Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.
de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rümke H, de Groot R, van Alphen L, van den Dobbelsteen G. de Kleijn E, et al. Among authors: van eijndhoven l, van alphen l, van dijken h, van den dobbelsteen g. Vaccine. 2001 Nov 12;20(3-4):352-8. doi: 10.1016/s0264-410x(01)00371-1. Vaccine. 2001. PMID: 11672897 Clinical Trial.
Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.
de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme GW, Wala M, Juttmann R, Rümke HC. de Kleijn ED, et al. Among authors: van omme gw, van alphen l, van den dobbelsteen g, van dijken h. Vaccine. 2000 Feb 14;18(15):1456-66. doi: 10.1016/s0264-410x(99)00423-5. Vaccine. 2000. PMID: 10618543 Clinical Trial.
Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP. Vermont CL, et al. Among authors: van limpt cj, van alphen l, van den dobbelsteen gp, van dijken hh. Infect Immun. 2002 Feb;70(2):584-90. doi: 10.1128/IAI.70.2.584-590.2002. Infect Immun. 2002. PMID: 11796586 Free PMC article. Clinical Trial.
In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components.
Stittelaar KJ, Boes J, Kersten GF, Spiekstra A, Mulder PG, de Vries P, Roholl PJ, Dalsgaard K, van den Dobbelsteen G, van Alphen L, Osterhaus AD. Stittelaar KJ, et al. Among authors: van alphen l, van den dobbelsteen g. Vaccine. 2000 May 22;18(23):2482-93. doi: 10.1016/s0264-410x(00)00026-8. Vaccine. 2000. PMID: 10775782
Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP. Vermont CL, et al. Among authors: van limpt cj, van alphen l, van den dobbelsteen gp, van der ende a, van dijken hh. Infect Immun. 2003 Apr;71(4):1650-5. doi: 10.1128/IAI.71.4.1650-1655.2003. Infect Immun. 2003. PMID: 12654777 Free PMC article. Clinical Trial.
76 results